The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario
May 1, 2014, 00:00
10.1016/j.jval.2014.03.523
https://www.valueinhealthjournal.com/article/S1098-3015(14)00574-9/fulltext
Title :
The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00574-9&doi=10.1016/j.jval.2014.03.523
First page :
A90
Section Title :
Cancer
Open access? :
No
Section Order :
1580